Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04344795
Title Phase 1a/1b Study of TPST-1495 Alone and With Pembrolizumab in Subjects With Solid Tumors
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Tempest Therapeutics
Indications

colorectal cancer

Advanced Solid Tumor

urinary bladder cancer

triple-receptor negative breast cancer

head and neck squamous cell carcinoma

stomach cancer

Therapies

TPST-1495

Pembrolizumab + TPST-1495

Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
University of Michigan Rogel Cancer Center Recruiting Ann Arbor Michigan 48109 United States Details
START Midwest Recruiting Grand Rapids Michigan 49546 United States Details
Carolina BioOncology Institute Recruiting Huntersville North Carolina 28078 United States Details
SCRI-OK Stephenson Cancer Center Recruiting Oklahoma City Oklahoma 73104 United States Details
University of Pittsburgh Medical Center Recruiting Pittsburgh Pennsylvania 15213 United States Details
Tennessee Oncology Recruiting Nashville Tennessee 37203 United States Details
South Texas Accelerated Research Therapeutics (START) Recruiting San Antonio Texas 78229 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field